search

Active clinical trials for "Crohn Disease"

Results 851-860 of 1510

Transition of Inflammatory Bowel Disease (IBD) Patients From Pediatric to Adult Gastroenterologist...

Inflammatory Bowel DiseasesCrohn's Disease1 more

The purpose of this study is to determine if the program that has been made to ease the transition of care for adolescent patients with IBD from pediatric gastroenterology to adult gastroenterology is effective to reduce the risk of disease flare during this period. Patient satisfaction with this program will also be assessed.

Terminated8 enrollment criteria

Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) Patients...

Crohn's Disease

To evaluate the relationship between noninvasive biomarkers (patient serological markers and metagenomic analysis of stool) and disease status as determined by colonoscopy and by clinical symptoms in patients with Crohn's disease, and to evaluate whether changes in the biomarker levels over time correlate to changes in the state of patients' disease.

Terminated17 enrollment criteria

Effect of Iron and Vitamin E Supplementation on Disease Activity in Patients With Either Crohn's...

Crohn's DiseaseUlcerative Colitis1 more

Hypothesis:In patients with ulcerative colitis and Crohn's disease diagnosed with mild or moderate anaemia: iron supplementation will increase disease activity and oxidative stress the addition of antioxidant vitamin will reduce this detrimental effect

Terminated6 enrollment criteria

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE...

Rheumatoid ArthritisInflammatory Arthritis6 more

The VaricElla zosteR VaccinE (VERVE) trial evaluates the safety and effectiveness of the Herpes zoster (HZ) vaccine for shingles, Zostavax, in patients over 50 years old with arthritis and other diseases who are using anti-tumor necrosis factor (TNF) therapy and who have not previously received the vaccine.

Completed24 enrollment criteria

The SpACE Study - Small Bowel Crohn's Disease and Spondyloarthropathies

SpondyloarthropathyCrohn Disease

Inflammatory bowel disease is clinically associated with spondylarthropathies in 5-15% of cases. Protocol colonoscopic assessment demonstrated asymptomatic inflammation characteristic of Crohn's disease in up to 1/3 of SpA patients. Videocapsule endoscopy is a superior diagnostic tool to detect small bowel mucosal pathology. However, it has been infrequently used to evaluate bowel inflammation in spondylarthropathies. This study compared the accuracy of videocapsule endoscopy to standard ileocolonoscopy for the detection of inflammatory bowel lesions in patients with spondylarthropathies, and to describe the clinical and laboratory predictors of small bowel inflammation in this cohort.

Completed2 enrollment criteria

Vedolizumab Post Op Study

Crohn's Disease

This is a pilot study that will determine the endoscopic recurrence of Crohn's disease 12 months after curative, resective ileal or ileocolonic surgery in patients receiving post-operative vedolizumab (Entyvio) or placebo. The investigators hypothesize that the administration of post-operative vedolizumab will decrease the endoscopic recurrence of Crohn's disease.

Withdrawn35 enrollment criteria

Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease

Crohns DiseaseCrohn's Disease

The study will include participants with moderate to severe Crohn's disease. The aim is to evaluate the safety, tolerability, and efficacy of anti-oncostatin M monoclonal antibody (mAb) GSK2330811. This is a parallel group study with Induction and Maintenance periods. During Induction, the first 100 participants randomised will receive a 450mg GSK2330811 SC loading dose followed by 150mg weekly (Q1W), or placebo for 12 weeks. Additional dose-ranging arms will open after the 100th participant is randomized and in addition to placebo and the highest dose arms will also include a 300mg subcutaneous (SC) loading dose followed by 150mg SC every 2 weeks (Q2W) arm, a 300mg loading dose followed by 150mg SC every 4 weeks (Q4W) arm and a 150mg SC every 8 weeks (Q8W) arm. Participants with a clinical response at Week 12 will continue into a 40-week blinded maintenance period and will receive either 150mg SC Q2W, 150mg SC Q4W, 150mg SC Q8W or placebo. Participants without a clinical response at Week 12 will be offered up to 40 weeks of open label treatment with GSK2330811. Approximately 560 participants will be screened to randomize 280.

Withdrawn50 enrollment criteria

Education Intervention on Vaccination Adherence Among Inflammatory Bowel Disease (IBD) Patients...

Crohn Disease (CD)Ulcerative Colitis (UC)1 more

A retrospective chart review and a six-month prospective outcome analysis aimed to evaluate the efficacy of a vaccination education intervention and vaccination adherence among IBD patients at Weill-Cornell Medical Center. It is hypothesized that a general vaccination education campaign will improve vaccination adherence rates for all IBD patients. Secondarily, it is hypothesized that an Human Papilloma Virus (HPV) vaccination intervention targeted at high-risk IBD patients will increase vaccination adherence among these patients.

Completed5 enrollment criteria

The Prediction of Anastomotic Insufficiency Risk After Colorectal Surgery (PANIC) Study

Anastomotic LeakColorectal Cancer4 more

The Prediction of Anastomotic Insufficiency risk after Colorectal surgery (PANIC) study aims to establish a machine-learning-based application that allows for accurate preoperative prediction of patients at risk for anastomotic insufficiency after colon and colorectal surgery.

Suspended7 enrollment criteria

Exclusive Enteral Nutrition vs. Infliximab in Chinese CD Patients

Crohn's DiseaseExclusive Enteral Nutrition2 more

prospectively compared Exclusive Enteral Nutrition with Infliximab in the clinical outcomes, mucosal healing, nutrition improvements, adverse effects and gastrointestinal microbiota changes on Chinese Children With active Crohn's Disease

Withdrawn11 enrollment criteria
1...858687...151

Need Help? Contact our team!


We'll reach out to this number within 24 hrs